University of Valencia

About: University of Valencia is a education organization based out in Valencia, Spain. It is known for research contribution in the topics: Population & Neutrino. The organization has 27096 authors who have published 65669 publications receiving 1765689 citations. The organization is also known as: Universitat de València & UV.

The nucleophilicity N index in organic chemistry

Abstract: The nucleophilicity N index (J. Org. Chem.2008, 73, 4615), the inverse of the electrophilicity, , and the recently proposed inverse of the electrodonating power, , (J. Org. Chem.2010, 75, 4957) have been checked toward (i) a series of single 5-substituted indoles for which rate constants are available, (ii) a series of para-substituted phenols, and for (iii) a series of 2,5-disubstituted bicyclic[2.2.1]hepta-2,5-dienes which display concurrently electrophilic and nucleophilic behaviors. While all considered indices account well for the nucleophilic behavior of organic molecules having a single substitution, the nucleophilicity N index works better for more complex molecules. Unlike, the inverse of the electrophilicity, , (R2 = 0.71), and the inverse of the electrodonating power, (R2 = 0.83), a very good correlation of the nucleophilicity N index of twelve 2-substituted-6-methoxy-bicyclic[2.2.1]hepta-2,5-dienes versus the activation energy associated with the nucleophilic attack on 1,1-dicyanoethylene is found (R2 = 0.99). This comparative study allows to assert that the nucleophilicity N index is a measure of the nucleophilicity of complex organic molecules displaying concurrently electrophilic and nucleophilic behaviors.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Abstract: Summary Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate and event-free survival. We report updated results from our primary analysis to establish the long-term benefit of trastuzumab-containing neoadjuvant therapy. Methods We did this multicentre, open-label, randomised trial in women with HER2-positive locally advanced or inflammatory breast cancer. Participants were randomly assigned (1:1), by computer program with a minimisation technique, to receive neoadjuvant chemotherapy alone or with 1 year of trastuzumab (concurrently with neoadjuvant chemotherapy and continued after surgery). A parallel group with HER2-negative disease was included and received neoadjuvant chemotherapy alone. Our primary endpoint was event-free survival. Analysis was by intention to treat. This study is registered at www.controlled-trials.com, ISRCTN86043495. Findings Between June 20, 2002, and Dec 12, 2005, we enrolled 235 patients with HER2-positive disease, of whom 118 received chemotherapy alone and 117 received chemotherapy plus trastuzumab. 99 additional patients with HER2-negative disease were included in the parallel cohort. After a median follow-up of 5·4 years (IQR 3·1–6·8) the event-free-survival benefit from the addition of trastuzumab to chemotherapy was maintained in patients with HER2-positive disease. 5 year event-free survival was 58% (95% CI 48–66) in patients in the trastuzumab group and 43% (34–52) in those in the chemotherapy group; the unadjusted hazard ratio (HR) for event-free survival between the two randomised HER2-positive treatment groups was 0·64 (95% CI 0·44–0·93; two-sided log-rank p=0·016). Event-free survival was strongly associated with pathological complete remission in patients given trastuzumab. Of the 68 patients with a pathological complete response (45 with trastuzumab and 23 with chemotherapy alone), the HR for event-free survival between those with and without trastuzumab was 0·29 (95% CI 0·11–0·78). During follow-up only four cardiovascular adverse events were regarded by the investigator to be drug-related (grade 2 lymphostasis and grade 2 lymphoedema, each in one patient in the trastuzumab group, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemotherapy-alone group). Interpretation These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in patients with locally advanced or inflammatory breast cancer, and provide new insight into the association between pathological complete remission and long-term outcomes in HER2-positive disease. Funding F Hoffmann-La Roche.

Unveiling $ν$ secrets with cosmological data: neutrino masses and mass hierarchy

Abstract: Using some of the latest cosmological data sets publicly available, we derive the strongest bounds in the literature on the sum of the three active neutrino masses, ${M}_{\ensuremath{ u}}$, within the assumption of a background flat $\mathrm{\ensuremath{\Lambda}}\mathrm{CDM}$ cosmology. In the most conservative scheme, combining Planck cosmic microwave background temperature anisotropies and baryon acoustic oscillations (BAO) data, as well as the up-to-date constraint on the optical depth to reionization ($\ensuremath{\tau}$), the tightest 95% confidence level upper bound we find is ${M}_{\ensuremath{ u}}l0.151\text{ }\text{ }\mathrm{eV}$. The addition of Planck high-$\ensuremath{\ell}$ polarization data, which, however, might still be contaminated by systematics, further tightens the bound to ${M}_{\ensuremath{ u}}l0.118\text{ }\text{ }\mathrm{eV}$. A proper model comparison treatment shows that the two aforementioned combinations disfavor the inverted hierarchy at $\ensuremath{\sim}64%\text{ }\text{ }\text{ }\mathrm{C}.\mathrm{L}.$ and $\ensuremath{\sim}71%\text{ }\text{ }\mathrm{C}.\mathrm{L}.$, respectively. In addition, we compare the constraining power of measurements of the full-shape galaxy power spectrum versus the BAO signature, from the BOSS survey. Even though the latest BOSS full-shape measurements cover a larger volume and benefit from smaller error bars compared to previous similar measurements, the analysis method commonly adopted results in their constraining power still being less powerful than that of the extracted BAO signal. Our work uses only cosmological data; imposing the constraint ${M}_{\ensuremath{ u}}g0.06\text{ }\text{ }\mathrm{eV}$ from oscillations data would raise the quoted upper bounds by $\mathcal{O}(0.1\ensuremath{\sigma})$ and would not affect our conclusions.

2020 global reassessment of the neutrino oscillation picture

Abstract: We present an updated global fit of neutrino oscillation data in the simplest three-neutrino framework In the present study we include up-to-date analyses from a number of experiments Concerning the atmospheric and solar sectors, besides the data considered previously, we give updated analyses of IceCube DeepCore and Sudbury Neutrino Observatory data, respectively We have also included the latest electron antineutrino data collected by the Daya Bay and RENO reactor experiments, and the long-baseline T2K and NOνA measurements, as reported in the Neutrino 2020 conference All in all, these new analyses result in more accurate measurements of θ13, θ12, $$ \Delta {m}_{21}^2 $$ and $$ \left|\Delta {m}_{31}^2\right| $$ The best fit value for the atmospheric angle θ23 lies in the second octant, but first octant solutions remain allowed at ∼ 24σ Regarding CP violation measurements, the preferred value of δ we obtain is 108π (158π) for normal (inverted) neutrino mass ordering The global analysis still prefers normal neutrino mass ordering with 25σ statistical significance This preference is milder than the one found in previous global analyses These new results should be regarded as robust due to the agreement found between our Bayesian and frequentist approaches Taking into account only oscillation data, there is a weak/moderate preference for the normal neutrino mass ordering of 200σ While adding neutrinoless double beta decay from the latest Gerda, CUORE and KamLAND-Zen results barely modifies this picture, cosmological measurements raise the preference to 268σ within a conservative approach A more aggressive data set combination of cosmological observations leads to a similar preference for normal with respect to inverted mass ordering, namely 270σ This very same cosmological data set provides 2σ upper limits on the total neutrino mass corresponding to Σmν < 012 (015) eV in the normal (inverted) neutrino mass ordering scenario The bounds on the neutrino mixing parameters and masses presented in this up-to-date global fit analysis include all currently available neutrino physics inputs